Back to Journals » Drug Design, Development and Therapy » Volume 9

Neuroprotective therapies for glaucoma

Authors Song W, Huang P, Zhang C

Received 8 January 2015

Accepted for publication 5 February 2015

Published 11 March 2015 Volume 2015:9 Pages 1469—1479

DOI https://doi.org/10.2147/DDDT.S80594

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Editor who approved publication: Prof. Dr. Wei Duan


Wei Song, Ping Huang, Chun Zhang

Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China

Abstract: Glaucoma is the second leading cause for blindness worldwide. It is mainly caused by glaucomatous optic neuropathy (GON) characterized by retinal ganglion cell loss, which leads to visual field defect and blindness. Up to now, the main purpose of antiglaucomatous therapies has been to lower intraocular pressure (IOP) through surgeries and medications. However, it has been found that progressive GON is still present in some patients with effective IOP decrease. Therefore, risk factors other than IOP elevation, like neurotrophin deprivation and excitotoxicity, contribute to progressive GON. Novel approaches of neuroprotection may be more effective for preserving the function of the optic nerve.

Keywords: glaucoma, glaucomatous optic neuropathy, retinal ganglion cells, neuro­protection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]